Dataset Information

Proteomics characterization of VPCs

ABSTRACT: hESCs were differentiated into vascular progenitor cells, using defined growth conditions. Initial population of SCs and the two derivative CD34 positive and CD34 negative populations were analyzed using mass spectrometry.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Konstantinos Tsolis

LAB HEAD: Anastasios (Tassos) Economou

PROVIDER: PXD003606 | Pride | 2016-09-28

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 181

Publications

Proteome Changes during Transition from Human Embryonic to Vascular Progenitor Cells.

Tsolis Konstantinos C KC Bagli Eleni E Kanaki Katerina K Zografou Sofia S Carpentier Sebastien S Bei Ekaterini S ES Christoforidis Savvas S Zervakis Michalis M Murphy Carol C Fotsis Theodore T Economou Anastassios A

Journal of proteome research 20160513 6

Human embryonic stem cells (hESCs) are promising in regenerative medicine (RM) due to their differentiation plasticity and proliferation potential. However, a major challenge in RM is the generation of a vascular system to support nutrient flow to newly synthesized tissues. Here we refined an existing method to generate tight vessels by differentiating hESCs in CD34(+) vascular progenitor cells using chemically defined media and growth conditions. We selectively purified these cells from CD34(-) ...[more]

PMID: 27146950

Similar Datasets

Project description:Ex vivo monitored human CD34+ stem cells (SCs) injected into myocardium scar tissue have shown real benefits for the recovery of patients with myocardial infarctions. They have been used previously in clinical trials with hopeful results and are expected to be promising for cardiac regenerative medicine following severe acute myocardial infarctions. However, some debates on their potential efficacy in cardiac regenerative therapies remain to be clarified. To elucidate the levels of CD34+ SCs implication and contribution in cardiac regeneration, better identification of the main regulators, pathways, and genes involved in their potential cardiovascular differentiation and paracrine secretion needs to be determined. We first developed a protocol thought to commit human CD34+ SCs purified from cord blood toward an early cardiovascular lineage. Then, by using a microarray-based approach, we followed their gene expression during differentiation. We compared the transcriptome of undifferentiated CD34+ cells to those induced at two stages of differentiation (i.e., day 3 and day 14), with human cardiomyocyte progenitor cells (CMPCs), as well as cardiomyocytes as controls. Interestingly, in the treated cells we observed an increase in the expressions of the main regulators usually present in cardiovascular cells. We identified cell surface markers of the cardiac mesoderm, such as kinase insert domain receptor (KDR) and the cardiogenic surface receptor Frizzled 4 (FZD4), induced in the differentiated cells in comparison to undifferentiated CD34+ cells. The Wnt and TGF- pathways appeared to be involved in this activation. This study underlined the real capacity of effectively stimulated CD34+ SCs to express cardiac markers and, once induced, allowed the identification of markers that are known to be involved in vascular and early cardiogenesis, demonstrating their potential priming towards cardiovascular cells. These findings could complement their paracrine positive effects known in cell therapy for heart disease and may help improve the efficacy and safety of using ex vivo expanded CD34+ SCs.

Project description:Human embryonic stem cells (hESCs) offer an important model for investigating the human hematopoietic celldevelopment. Here, we used long serial analysis of gene expression and quantitative real-time PCR to characterize two subsets of primitive hematopoietic cells derived in vitro from hESCs. This revealed differences in their expression of genes associated with lymphoid and myeloid development, cellular biosynthetic processes, and cell cycle regulation. Further comparisons with analogous data for primitive hematopoietic cells isolated from first trimester human fetal liver and newborn cord blood showed a strong similarity between the transcriptomes of the most primitive hESC- and in vivo-derived populations, with the main differences involving genes that regulate HSC development, self-renewal and homing, chromatin remodeling, AP1 transcription complex genes, and non-coding RNAs. These data suggest that primitive hematopoietic cells are generated from hESCs in vitro by processes similar to those operative during human embryogenesis in vivo, although some differences were also detected. Human embryonic stem cells (hESCs) are capable of indefinite self-renewal but can also be induced to undergo a stepwise process of differentiation into a spectrum of recognizable mature blood cell types. However, a clear understanding of the molecular mechanism by which the first hematopoietic stem cells (HSCs) acquire their unique defining properties of self-renewal and repopulating potential is lacking. As a first step towards obtaining the information needed to close this gap, we have undertaken a comparative gene expression analysis of different highly purified primitive human hematopoietic subpopulations (erythroid-megakaryocytic progenitor enriched CD43+CD235a+CD41a+/- cells, mutiplepotent progenitor enriched lin-CD34+CD43+CD45-, and lin-CD34+CD43+CD45+ cells) generated either in vitro from hESCs or in vivo from fetal (human fetal liver lin-CD34+CD38- cells) or neonatal hematopoietic primitive cells (human cord blood lin-CD34+CD38- and lin-CD34+CD38+ cells). This involved preparing a long serial analysis of gene expression (LongSAGE) library from an extracts of each prospectively isolated subpopulation and then sequencing each library to a depth of 200,000 tags.

			Action	DRS
	CD-10_5th.raw	Raw
	CD-1_5th.raw	Raw
	CD-2_5th.raw	Raw
	CD-3_5th.raw	Raw
	CD-4_5th.raw	Raw